PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-10-02 close
NeoImmuneTech has secured its first commercial revenue through the North American launch of Endari, while advancing NT-I7 commercialization along two tracks: acute radiation syndrome (ARS) and CAR-T combination therapy.
US sales of the rare-disease drug Endari began in the first half of 2026, lifting quarterly revenue well above the 2025 average.
In August 2026, the company signed a licensing deal worth up to $260 million with US-based Tolerance Bio for NT-I7's thymic dysfunction indication.
NT-I7 is pursuing the FDA's Animal Rule pathway as an ARS treatment, with engagement in the BARDA BAA program aimed at linking to US government procurement.
The CAR-T combination trial (NIT-126) advanced to a 720µg/kg dose-escalation cohort after no dose-limiting toxicity was observed at 600µg/kg.
Both annual operating and net losses have narrowed each year since 2022, and 2025 total equity rose from the prior year on the back of a capital raise.
Founded in Maryland in 2014, NeoImmuneTech listed on KOSDAQ in 2021 under the technology growth company special listing track, operating as a T cell-based immunotherapy biotech.
Its core pipeline asset is the long-acting interleukin-7 fusion protein NT-I7 (efineptakin alfa), built on a T cell expansion mechanism applied across multiple indications as a platform strategy.
The company has formalized a 'focus and selectivity' approach, splitting NT-I7 development into immuno-oncology (CAR-T combination), acute radiation syndrome (ARS) treatment, and thymic dysfunction, outsourcing areas it cannot develop directly to partners.
In August 2026, it licensed exclusive development and commercialization rights for thymic dysfunction indications, including HIV-related immune reconstitution, in the Americas and Europe to US biotech Tolerance Bio, while retaining its immuno-oncology rights in-house.
In December 2025, the company also acquired North American marketing rights for the sickle cell disease drug Endari from Emmaus Life Sciences, beginning US sales in the first half of 2026 and shifting toward a structure that combines R&D with commercial revenue.
In the CAR-T combination field, an investigator-initiated trial led by physicians at Washington University administers NT-I7 following approved CAR-T therapies such as Yescarta or Breyanzi, while a joint research collaboration with Immunocore's ImmTAC platform is also being explored for combination potential.
The largest shareholder is Genexine, holding a 16.63% stake as of the end of September 2025.
As a clinical-stage biotech with still nascent revenue, the company's competitive landscape is shaped by rivalry among global IL-7 class developers and big pharma or biotech players with CAR-T persistence-enhancing technologies for partnership opportunities.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩24,338,357 | -₩6.6B | −27107.9% |
| 2025Q3 | ₩17,965,443 | -₩4.4B | −24577.2% |
| 2025Q4 | ₩37,391,547 | -₩5.8B | −15603.0% |
| 2026Q1 | ₩500M | -₩5.9B | −1180.5% |
| 2026Q2 | ₩1.1B | -₩3.9B | −359.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩0 | -₩62.4B | -₩64.7B | — | −49.5% | 16.9% |
| 2023 | ₩0 | -₩59B | -₩56.6B | — | −70.5% | 20.9% |
| 2024 | ₩200M | -₩40.6B | -₩41.5B | −23497.6% | −105.8% | 57.0% |
| 2025 | ₩92,309,646 | -₩24.6B | -₩31B | −26596.6% | −54.2% | 38.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 was about KRW 90 million, down from roughly KRW 170 million in 2024, while operating loss narrowed from about KRW 40.6 billion in 2024 to about KRW 24.6 billion in 2025, and net loss attributable to owners shrank from about KRW 41.5 billion to about KRW 31.0 billion over the same period.
Looking at the multi-year trend since 2022, operating losses have declined for four consecutive years, from roughly KRW 62.4 billion in 2022 to KRW 59.0 billion in 2023, KRW 40.6 billion in 2024, and KRW 24.6 billion in 2025.
On a quarterly basis, revenue stayed minimal at about KRW 18 million in Q3 2025 and KRW 37 million in Q4 2025 before jumping to roughly KRW 498 million in Q1 2026 and KRW 1.09 billion in Q2 2026, a move attributable to the start of Endari sales in the US.
Operating losses also eased gradually on a quarterly basis, from about KRW 6.6 billion in Q2 2025 to roughly KRW 3.9 billion in Q2 2026.
Net loss attributable to owners widened to about KRW 10.3 billion in Q4 2025 before narrowing to roughly KRW 7.1 billion in Q1 2026 and sharply to about KRW 0.4 billion in Q2 2026, a move likely reflecting both the narrower operating loss and the impact of non-operating items.
Total equity attributable to owners fell from about KRW 130.8 billion in 2022 to KRW 80.4 billion in 2023 and KRW 39.2 billion in 2024 as accumulated losses mounted, then rose to about KRW 57.1 billion in 2025, a recovery explained by a rights offering completed in September 2025 (issue price of KRW 721, with a target of KRW 65 billion).
The debt ratio fell from 57.0% in 2024 to 38.6% in 2025, and operating cash outflow also improved, narrowing from about negative KRW 53.4 billion in 2023 to about negative KRW 24.4 billion in 2025.
In immuno-oncology, CAR-T therapies have been commercialized for blood cancers but have yet to gain approval for solid tumors, and limited cell persistence after infusion remains a common industry challenge.
Long-acting IL-7 agents such as NT-I7 are drawing attention as combination options to enhance CAR-T expansion and persistence, with multiple global biotechs besides NeoImmuneTech exploring similar cytokine-based combination strategies.
The ARS treatment market differs from conventional pharmaceutical markets in that it is procurement-driven, based on government stockpiling demand; since most approved ARS treatments focus on neutrophil or platelet recovery mechanisms, NT-I7's lymphocyte-recovery mechanism stands out as a differentiator.
However, market entry for ARS treatments requires prior evaluation through the US BARDA BAA program and FDA Animal Rule approval, a regulatory and procurement pathway distinct from the conventional Phase 3 clinical route.
In Europe, rising defense budgets tied to geopolitical tensions and nuclear risk response are cited as a potential driver for expanding regional demand for ARS treatments.
The sickle cell disease treatment market already has established approved drugs like Endari listed with US pharmacy benefit managers (PBMs), offering a relatively stable revenue base given the limited treatment options for this rare disease.
Overall, NeoImmuneTech remains at an early commercialization stage with still-small revenue scale, and competition is shaped less by market share in individual products than by rivalry to secure global partnerships.
The company has designated 2026 as a 'revenue generation turning point,' stating its plan to simultaneously expand Endari sales and pursue NT-I7 licensing deals.
According to July 2026 IR materials, available cash stood at about KRW 45 billion as of end-June 2026, with roughly KRW 10 billion in remaining convertible bonds, which the company said would allow operations through 2027 without additional fundraising.
For ARS treatment development, a key efficacy study using a primate model is underway, with company representatives having projected final data availability sometime in 2026.
The NT-I7-based CAR-T combination trial (NIT-126) advanced to a 720µg/kg dose-escalation cohort after no dose-limiting toxicity was observed at the 600µg/kg level, and the effect of the redesigned protocol—with earlier and more frequent dosing—remains to be further confirmed.
Under the Tolerance Bio agreement, the partner will pay NeoImmuneTech staged milestones tied to clinical development and sales targets, and Tolerance Bio has indicated a goal of initiating Phase 2 trials for the related indication sometime in 2027.
The Endari business is at a stage of pursuing margin improvement through selective marketing investment, with the company stating that some level of operating profit generation is possible even at current sales volumes.
However, with ARS treatment approval not expected before 2028 at the earliest, commercialization of key pipeline assets still requires a multi-year horizon.
The current share price trades at a level modestly above net asset value on a self-calculated basis, while persistent net losses make conventional price-to-earnings analysis of limited usefulness.
While the scale of net losses has narrowed each year from 2022 through 2025, the company has not yet reached profitability, which constrains profitability-based valuation approaches.
There is no dividend payment history, making dividend-related metrics inapplicable, a common feature for clinical-stage biotech companies.
The repeated rights offerings and third-party share placements across 2025 and 2026, which increased the share count, are a factor worth considering when interpreting per-share metrics.
Ultimately, the current valuation appears to reflect market expectations around future events—such as Endari sales expansion and progress on NT-I7 licensing and ARS approval—more than past financial performance.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Endari sales in the US gained momentum from the first half of 2026, lifting quarterly revenue by multiples versus the 2025 average. The company has pointed to potential margin improvement through selective marketing in a rare-disease market with limited treatment options. The shift from a pure R&D-focused biotech toward one with commercial revenue can be viewed positively.
The up-to-$260 million agreement with Tolerance Bio in August 2026 marks the company's first licensing deal since its KOSDAQ listing, which can be interpreted as external validation of NT-I7's platform value.
The upfront payment was received as a 4% equity stake rather than cash, leaving room for additional value appreciation tied to the partner's growth. Core immuno-oncology rights were excluded from the deal, preserving the company's own development capacity.
Unlike existing approved ARS treatments, NT-I7 is differentiated by its mechanism of increasing absolute lymphocyte count, and it is pursuing an approval pathway based on animal data under the FDA's Animal Rule rather than human trials.
ARS treatments operate in a procurement-driven market based on government stockpiling demand, which could support a recurring revenue structure post-approval. The company has been expanding its engagement with the US government through participation in the BARDA BAA program.
Operating losses in the tens of billions of won have persisted every year from 2022 through 2025, with revenue remaining very small relative to losses. While a narrowing trend in losses is evident, a turn to profitability has not yet come into view. Even as Endari sales grow, the scale remains insufficient to cover NT-I7 R&D spending.
A rights offering in September 2025 and a third-party share placement in June-July 2026 both increased the share count in succession. Given the ongoing loss structure, additional dilution cannot be ruled out if further fundraising becomes necessary. Outstanding convertible bonds also remain a factor that could alter share count upon conversion.
Industry projections suggest ARS treatment approval is unlikely before 2028 at the earliest, meaning commercialization still requires a multi-year horizon. Cooperation with BARDA remains at a technology-sharing stage, with no confirmed purchase volumes or pricing terms yet. The approval strategy itself could also shift depending on the outcome of primate study data.
The CAR-T combination trial (NIT-126) remains at an early dose-escalation stage, requiring more time before efficacy data becomes available. ARS treatments must navigate the relatively uncommon FDA Animal Rule pathway, carrying different uncertainties than a conventional Phase 3 trial.
CAR-T combination efficacy in solid tumors remains an uncharted area with no FDA-approved precedent, requiring further validation.
As of end-June 2026, available cash was about KRW 45 billion with roughly KRW 10 billion in remaining convertible bonds, and the company stated it can operate through 2027 without additional funding, though its funding plans beyond that point warrant monitoring given the ongoing loss structure.
Considering the history of repeated capital raises in recent years, the need for further fundraising could resurface. Milestones and royalties from licensing agreements are tied to clinical, regulatory, and sales performance, making their timing and scale uncertain.
Endari revenue remains at an early stage, and the company's mid-to-long-term value depends heavily on further NT-I7 licensing deals and progress toward ARS approval. Delays or breakdowns in partnership discussions with global pharma companies could affect the growth trajectory.
Given a business structure concentrated on a small number of pipeline assets, negative data from any single program could have a relatively outsized impact on overall company value.
The Q3 quarterly report is expected to be disclosed, making it worth checking whether Endari revenue continues its quarter-over-quarter growth and whether operating losses keep narrowing.
Final data from the key primate-model efficacy study for the ARS treatment is anticipated around this time, which could clarify the direction of the FDA Animal Rule approval strategy.
Monitoring the DSMB review outcome for the 720µg/kg cohort of the NIT-126 trial and whether further dose escalation proceeds will help assess the effect of the redesigned CAR-T combination protocol.
Checking whether Tolerance Bio announces the start of Phase 2 trials related to TLB-33 and completion of its targeted investment round will help gauge how the partner's funding capacity affects the pace of NT-I7 development.
NeoImmuneTech secured its first commercial revenue through Endari's US sales launch starting in the first half of 2026, and in August signed a licensing agreement with Tolerance Bio for NT-I7, adding an external validation point for its platform value.
Both annual operating and net losses have continued narrowing each year since 2022, and 2025 total equity also rose year-over-year due to a capital raise.
However, revenue remains very small relative to losses, and with ARS treatment approval not expected before 2028 at the earliest, commercialization of core pipeline assets still requires a multi-year horizon.
Repeated capital raises and outstanding convertible bonds remain factors that could affect share count, which is worth considering when interpreting per-share metrics.
Progress in the CAR-T combination trial's dose-escalation stage, data from BARDA/ARS-related work, and news of further licensing deals are likely to be the key variables shaping the company's future direction.
Report written 2026-10-03 · Data as of 2026-10-02
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.